http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 05 Aug 2026 09:37:10 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+PT+Change/TransMedics+Group+%28TMDX%29+PT+Lowered+to+%2477+at+UBS/26871555.html UBS analyst Patrick Wood lowered the price target on TransMedics Group (NASDAQ: TMDX) to $77.00 (from $80.00) while maintaining a Neutral rating. http://www.streetinsider.com/Analyst+PT+Change/TransMedics+Group+%28TMDX%29+PT+Lowered+to+%2477+at+UBS/26871555.html Wed, 05 Aug 2026 09:37:10 -0400 TMDX http://www.streetinsider.com/Analyst+PT+Change/TransMedics+Group+%28TMDX%29+PT+Lowered+to+%2465+at+Stifel/26870788.html Stifel analyst Thomas Stephan lowered the price target on TransMedics Group (NASDAQ: TMDX) to $65.00 (from $80.00) while maintaining a Hold rating. http://www.streetinsider.com/Analyst+PT+Change/TransMedics+Group+%28TMDX%29+PT+Lowered+to+%2465+at+Stifel/26870788.html Wed, 05 Aug 2026 08:24:25 -0400 TMDX http://www.streetinsider.com/Analyst+PT+Change/TransMedics+Group+%28TMDX%29+PT+Lowered+to+%2492+at+JPMorgan/26870761.html JPMorgan analyst Allen Gong lowered the price target on TransMedics Group (NASDAQ: TMDX) to $92.00 (from $100.00) while maintaining a Neutral rating. http://www.streetinsider.com/Analyst+PT+Change/TransMedics+Group+%28TMDX%29+PT+Lowered+to+%2492+at+JPMorgan/26870761.html Wed, 05 Aug 2026 08:17:20 -0400 TMDX http://www.streetinsider.com/Analyst+PT+Change/TransMedics+Group+%28TMDX%29+PT+Lowered+to+%24100+at+Piper+Sandler/26870106.html Piper Sandler analyst Matt O'Brien lowered the price target on TransMedics Group (NASDAQ: TMDX) to $100.00 (from $120.00) while maintaining a Overweight rating. http://www.streetinsider.com/Analyst+PT+Change/TransMedics+Group+%28TMDX%29+PT+Lowered+to+%24100+at+Piper+Sandler/26870106.html Wed, 05 Aug 2026 07:03:42 -0400 TMDX http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++TransMedics+Group%2C+Inc.+++For%3A+Jun+30/26866639.html si-local-file:///var/storage/secattach/20260804/26866639.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++TransMedics+Group%2C+Inc.+++For%3A+Jun+30/26866639.html Tue, 04 Aug 2026 16:16:00 -0400 O.00051745 TMDX http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++TransMedics+Group%2C+Inc.+++For%3A+Jun+30/26866639.html si-local-file:///var/storage/secattach/20260804/26866639.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++TransMedics+Group%2C+Inc.+++For%3A+Jun+30/26866639.html Tue, 04 Aug 2026 16:16:00 -0400 O.00051745 TMDX http://www.streetinsider.com/Press+Releases/TransMedics+Reports+Second+Quarter+2026+Financial+Results/26866076.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.andver" idsrc="xmltag.org" >ANDOVER, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 4, 2026</chron></span> /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended <chron>June 30, 2026</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS233956/TransMedics-Logo.jpg?id=OA2824499" title="TransMedics Logo. (PRNewsFoto/TransMedics, Inc.)" alt="TransMedics Logo. (PRNewsFoto/TransMedics, Inc.)" /> http://www.streetinsider.com/Press+Releases/TransMedics+Reports+Second+Quarter+2026+Financial+Results/26866076.html Tue, 04 Aug 2026 16:05:00 -0400 O.00051745 TMDX http://www.streetinsider.com/Press+Releases/TransMedics+Reports+Second+Quarter+2026+Financial+Results/26866076.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.andver" idsrc="xmltag.org" >ANDOVER, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 4, 2026</chron></span> /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended <chron>June 30, 2026</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS233956/TransMedics-Logo.jpg?id=OA2824499" title="TransMedics Logo. (PRNewsFoto/TransMedics, Inc.)" alt="TransMedics Logo. (PRNewsFoto/TransMedics, Inc.)" /> http://www.streetinsider.com/Press+Releases/TransMedics+Reports+Second+Quarter+2026+Financial+Results/26866076.html Tue, 04 Aug 2026 16:05:00 -0400 O.00051745 TMDX http://www.streetinsider.com/PRNewswire/TransMedics+Reports+Second+Quarter+2026+Financial+Results/26866076.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.andver" idsrc="xmltag.org" >ANDOVER, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 4, 2026</chron></span> /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended <chron>June 30, 2026</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS233956/TransMedics-Logo.jpg?id=OA2824499" title="TransMedics Logo. (PRNewsFoto/TransMedics, Inc.)" alt="TransMedics Logo. (PRNewsFoto/TransMedics, Inc.)" /> http://www.streetinsider.com/PRNewswire/TransMedics+Reports+Second+Quarter+2026+Financial+Results/26866076.html Tue, 04 Aug 2026 16:05:00 -0400 O.00051745 TMDX http://www.streetinsider.com/PRNewswire/TransMedics+Reports+Second+Quarter+2026+Financial+Results/26866076.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.andver" idsrc="xmltag.org" >ANDOVER, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 4, 2026</chron></span> /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended <chron>June 30, 2026</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS233956/TransMedics-Logo.jpg?id=OA2824499" title="TransMedics Logo. (PRNewsFoto/TransMedics, Inc.)" alt="TransMedics Logo. (PRNewsFoto/TransMedics, Inc.)" /> http://www.streetinsider.com/PRNewswire/TransMedics+Reports+Second+Quarter+2026+Financial+Results/26866076.html Tue, 04 Aug 2026 16:05:00 -0400 O.00051745 TMDX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++TransMedics+Group%2C+Inc.+++For%3A+Aug+04/26866139.html si-local-file:///var/storage/secattach/20260804/26866139.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++TransMedics+Group%2C+Inc.+++For%3A+Aug+04/26866139.html Tue, 04 Aug 2026 16:05:00 -0400 O.00051745 TMDX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++TransMedics+Group%2C+Inc.+++For%3A+Aug+04/26866139.html si-local-file:///var/storage/secattach/20260804/26866139.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++TransMedics+Group%2C+Inc.+++For%3A+Aug+04/26866139.html Tue, 04 Aug 2026 16:05:00 -0400 O.00051745 TMDX http://www.streetinsider.com/Press+Releases/TransMedics+Reports+Inducement+Grants+Under+NASDAQ+Listing+Rule+5635%28c%29%284%29/26857680.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.andver" idsrc="xmltag.org" >ANDOVER, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 3, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:TMDX" idsrc="xmltag.org" >TransMedics Group, Inc.</span> ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on <chron>July 29, 2026</chron>, TransMedics granted non-qualified stock options to purchase an aggregate of 18,762 shares of its common stock and an aggregate of 12,414 restricted stock units to 9 employees, each as a material inducement for each employee's entry into employment with TransMedics. The grants were approved by the Compensation Committee of the TransMedics Board http://www.streetinsider.com/Press+Releases/TransMedics+Reports+Inducement+Grants+Under+NASDAQ+Listing+Rule+5635%28c%29%284%29/26857680.html Mon, 03 Aug 2026 16:05:00 -0400 O.00051745 TMDX http://www.streetinsider.com/Press+Releases/TransMedics+Reports+Inducement+Grants+Under+NASDAQ+Listing+Rule+5635%28c%29%284%29/26857680.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.andver" idsrc="xmltag.org" >ANDOVER, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 3, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:TMDX" idsrc="xmltag.org" >TransMedics Group, Inc.</span> ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on <chron>July 29, 2026</chron>, TransMedics granted non-qualified stock options to purchase an aggregate of 18,762 shares of its common stock and an aggregate of 12,414 restricted stock units to 9 employees, each as a material inducement for each employee's entry into employment with TransMedics. The grants were approved by the Compensation Committee of the TransMedics Board http://www.streetinsider.com/Press+Releases/TransMedics+Reports+Inducement+Grants+Under+NASDAQ+Listing+Rule+5635%28c%29%284%29/26857680.html Mon, 03 Aug 2026 16:05:00 -0400 O.00051745 TMDX http://www.streetinsider.com/PRNewswire/TransMedics+Reports+Inducement+Grants+Under+NASDAQ+Listing+Rule+5635%28c%29%284%29/26857680.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.andver" idsrc="xmltag.org" >ANDOVER, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 3, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:TMDX" idsrc="xmltag.org" >TransMedics Group, Inc.</span> ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on <chron>July 29, 2026</chron>, TransMedics granted non-qualified stock options to purchase an aggregate of 18,762 shares of its common stock and an aggregate of 12,414 restricted stock units to 9 employees, each as a material inducement for each employee's entry into employment with TransMedics. The grants were approved by the Compensation Committee of the TransMedics Board http://www.streetinsider.com/PRNewswire/TransMedics+Reports+Inducement+Grants+Under+NASDAQ+Listing+Rule+5635%28c%29%284%29/26857680.html Mon, 03 Aug 2026 16:05:00 -0400 O.00051745 TMDX http://www.streetinsider.com/PRNewswire/TransMedics+Reports+Inducement+Grants+Under+NASDAQ+Listing+Rule+5635%28c%29%284%29/26857680.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.andver" idsrc="xmltag.org" >ANDOVER, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 3, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:TMDX" idsrc="xmltag.org" >TransMedics Group, Inc.</span> ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on <chron>July 29, 2026</chron>, TransMedics granted non-qualified stock options to purchase an aggregate of 18,762 shares of its common stock and an aggregate of 12,414 restricted stock units to 9 employees, each as a material inducement for each employee's entry into employment with TransMedics. The grants were approved by the Compensation Committee of the TransMedics Board http://www.streetinsider.com/PRNewswire/TransMedics+Reports+Inducement+Grants+Under+NASDAQ+Listing+Rule+5635%28c%29%284%29/26857680.html Mon, 03 Aug 2026 16:05:00 -0400 O.00051745 TMDX http://www.streetinsider.com/Analyst+PT+Change/TransMedics+Group+%28TMDX%29+PT+Lowered+to+%24106+at+Needham/26853823.html (Updated - August 3, 2026 7:12 AM EDT) <p>Needham analyst Mike Matson lowered the price target on TransMedics Group (NASDAQ: TMDX) to $106.00 (from $142.00) while maintaining a Buy rating.</p><p>The analyst commented: "We are shifting our organ transplant tracker to a quarterly publication from a monthly publication. Additionally, we have reviewed the performance of our prior trackers. Based on our prior trackers which included all three months of SRTR data for a given quarter, we accurately predicted whether TMDX would beat or miss consensus in 3 of 5 quarters (see Figure 1). Based on the SRTR data for April through June, http://www.streetinsider.com/Analyst+PT+Change/TransMedics+Group+%28TMDX%29+PT+Lowered+to+%24106+at+Needham/26853823.html Mon, 03 Aug 2026 07:12:55 -0400 TMDX http://www.streetinsider.com/Analyst+Comments/TransMedics+Group+%28TMDX%29+PT+Lowered+to+%24106+at+Needham/26853823.html (Updated - August 3, 2026 7:12 AM EDT) <p>Needham analyst Mike Matson lowered the price target on TransMedics Group (NASDAQ: TMDX) to $106.00 (from $142.00) while maintaining a Buy rating.</p><p>The analyst commented: "We are shifting our organ transplant tracker to a quarterly publication from a monthly publication. Additionally, we have reviewed the performance of our prior trackers. Based on our prior trackers which included all three months of SRTR data for a given quarter, we accurately predicted whether TMDX would beat or miss consensus in 3 of 5 quarters (see Figure 1). Based on the SRTR data for April through June, http://www.streetinsider.com/Analyst+Comments/TransMedics+Group+%28TMDX%29+PT+Lowered+to+%24106+at+Needham/26853823.html Mon, 03 Aug 2026 07:12:55 -0400 TMDX http://www.streetinsider.com/Press+Releases/TransMedics+to+Present+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26827572.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.andver" idsrc="xmltag.org" >ANDOVER, Mass.</location></span>, <span class="legendSpanClass"><chron>July 28, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:TMDX" idsrc="xmltag.org" >TransMedics Group, Inc.</span> ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in the Canaccord Genuity 46^th Annual Growth Conference in <location value="LU/us.ma.boston" idsrc="xmltag.org" >Boston</location> on <chron>Tuesday, August 11, 2026</chron>. The TransMedics management team will present beginning at <chron>2:00 p.m. ET</chron>/ <chron>1:00 p.m. CT</chron></p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/TransMedics+to+Present+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26827572.html Tue, 28 Jul 2026 16:29:00 -0400 O.00051745 TMDX http://www.streetinsider.com/Press+Releases/TransMedics+to+Present+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26827572.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.andver" idsrc="xmltag.org" >ANDOVER, Mass.</location></span>, <span class="legendSpanClass"><chron>July 28, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:TMDX" idsrc="xmltag.org" >TransMedics Group, Inc.</span> ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in the Canaccord Genuity 46^th Annual Growth Conference in <location value="LU/us.ma.boston" idsrc="xmltag.org" >Boston</location> on <chron>Tuesday, August 11, 2026</chron>. The TransMedics management team will present beginning at <chron>2:00 p.m. ET</chron>/ <chron>1:00 p.m. CT</chron></p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/TransMedics+to+Present+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26827572.html Tue, 28 Jul 2026 16:29:00 -0400 O.00051745 TMDX http://www.streetinsider.com/PRNewswire/TransMedics+to+Present+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26827572.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.andver" idsrc="xmltag.org" >ANDOVER, Mass.</location></span>, <span class="legendSpanClass"><chron>July 28, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:TMDX" idsrc="xmltag.org" >TransMedics Group, Inc.</span> ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in the Canaccord Genuity 46^th Annual Growth Conference in <location value="LU/us.ma.boston" idsrc="xmltag.org" >Boston</location> on <chron>Tuesday, August 11, 2026</chron>. The TransMedics management team will present beginning at <chron>2:00 p.m. ET</chron>/ <chron>1:00 p.m. CT</chron></p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/TransMedics+to+Present+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26827572.html Tue, 28 Jul 2026 16:29:00 -0400 O.00051745 TMDX http://www.streetinsider.com/PRNewswire/TransMedics+to+Present+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26827572.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.andver" idsrc="xmltag.org" >ANDOVER, Mass.</location></span>, <span class="legendSpanClass"><chron>July 28, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:TMDX" idsrc="xmltag.org" >TransMedics Group, Inc.</span> ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in the Canaccord Genuity 46^th Annual Growth Conference in <location value="LU/us.ma.boston" idsrc="xmltag.org" >Boston</location> on <chron>Tuesday, August 11, 2026</chron>. The TransMedics management team will present beginning at <chron>2:00 p.m. ET</chron>/ <chron>1:00 p.m. CT</chron></p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/TransMedics+to+Present+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26827572.html Tue, 28 Jul 2026 16:29:00 -0400 O.00051745 TMDX http://www.streetinsider.com/New+Coverage/UBS+Starts+TransMedics+Group+%28TMDX%29+at+Neutral/26821265.html <p>UBS initiates coverage on TransMedics Group (NASDAQ: TMDX) with a Neutral rating and a price target of $80.00.</p> <p>For an analyst ratings summary and ratings history on TransMedics Group <a href="http://www.streetinsider.com/rating_history.php?q=TMDX">click here</a>. For more ratings news on TransMedics Group <a href="http://www.streetinsider.com/stock_lookup_news.php?q=TMDX&amp;type=analyst">click here</a>.</p> <p>Shares of TransMedics Group closed at $74.28 yesterday.</p> http://www.streetinsider.com/New+Coverage/UBS+Starts+TransMedics+Group+%28TMDX%29+at+Neutral/26821265.html Tue, 28 Jul 2026 05:33:58 -0400 TMDX http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+TransMedics+Group+%28TMDX%29%3A+%27Assessing+the+%242.2B+U.S.+Kidney+Opportunity%27/26799385.html <p>Piper Sandler analyst Matt O'Brien reiterated an Overweight rating and $120.00 price target on TransMedics Group (NASDAQ: TMDX).</p><p>The analyst commented: "Assessing the $2.2B U.S. Kidney Opportunity; With TransMedics expected to submit its IDE for kidney in early 2027, we dig into the unmet need, clinical data, and market opportunity. Normothermic machine perfusion (NMP) has the opportunity to displace standard of care (hypothermic MP) by enabling real-time assessment and improving transplant logistics that should lower the very high non-use rates and expand the donor pool. There are questions about its ability to improve DGF, pricing, the reimbursement landscape, and market share http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+TransMedics+Group+%28TMDX%29%3A+%27Assessing+the+%242.2B+U.S.+Kidney+Opportunity%27/26799385.html Wed, 22 Jul 2026 09:26:54 -0400 TMDX http://www.streetinsider.com/Press+Releases/TransMedics+to+Report+Second+Quarter+2026+Financial+Results+on+August+4%2C+2026/26795566.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.andver" idsrc="xmltag.org" >ANDOVER, Mass.</location></span>, <span class="legendSpanClass"><chron>July 21, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:TMDX" idsrc="xmltag.org" >TransMedics Group, Inc.</span> ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the second quarter 2026 after market close on <chron>Tuesday, August 4, 2026</chron>. The TransMedics management team will host a corresponding conference call beginning at <chron>4:30 p.m. ET</chron> / <chron>1:30 p.m. PT</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/TransMedics+to+Report+Second+Quarter+2026+Financial+Results+on+August+4%2C+2026/26795566.html Tue, 21 Jul 2026 16:05:00 -0400 O.00051745 TMDX